GlassScriptPhysician profile
Thomas S Edwards
NPI 1639163215
$1,844.10
in general payments reported to CMS, 2019-2025
9 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $399 · 2021: $145 · 2022: $91.33 · 2023: $51.64 · 2024: $183 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,260.25 | 2019-2025 | Accent, Aveir, Jot Dx |
| Medtronic Vascular, INC. | $295.17 | 2019 | |
| Biotronik INC. | $127.56 | 2019 | |
| Boston Scientific Corporation | $81.63 | 2019-2021 | |
| International Rehabilitative Sciences, INC | $38.87 | 2025 | Rs-4i Plus With Intersperse |
| Regeneron Healthcare Solutions, INC. | $15.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.